

## Mario Niepel, Ph.D.

Department of Systems Biology and Laboratory of Systems Pharmacology  
Harvard Medical School  
200 Longwood Ave, WAB 444, Boston, MA 02115  
(617) 646-9094 (phone) – (617) 432-6990 (fax)  
mario\_niepel@hms.harvard.edu – [http://scholar.harvard.edu/mario\\_niepel](http://scholar.harvard.edu/mario_niepel)

---

### Education

Ph.D., Cell Biology, The Rockefeller University, New York, NY, USA 1998-2005  
Thesis Title: *The Myosin-like Proteins in S. cerevisiae: Multifunctional, Structural Components of the Nuclear Envelope.*  
Advisor: Michael P. Rout, Ph.D.

M.S., Biochemistry, UC Riverside, Riverside, CA, USA 1997-1998  
Thesis Title: *Characterization of the Cap-independent Translational Enhancement Conferred by the 5' Leader of the Tobacco Etch Virus.*  
Advisor: Daniel R. Gallie, Ph.D.

Diplom, Molecular Biology, RWTH Aachen, Aachen, Germany 1991-1997  
Thesis Title: *The Effect of mRNA Secondary Structure within the 3' UTR on Translation.*  
Advisor: Prof. Dr. Fritz M. Kreuzaler

### Appointments

Instructor 2013-present  
Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA

Instructor 2010-present  
Department of Systems Biology, Harvard Medical School, Boston, MA, USA

Postdoctoral Fellow 2006-2010  
Supervisor: Peter K. Sorger, Ph.D.  
Department of Systems Biology, Harvard Medical School, Boston, MA, USA

Postdoctoral Fellow 2006  
Supervisor: Peter K. Sorger, Ph.D.  
Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA

Postdoctoral Fellow 2005  
Supervisor: Michael P. Rout, Ph.D.  
Laboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, USA

### Other Positions and Employment

Scientific Coordinator of the NIH-Common Fund Library of Integrated Network-based Cellular Signatures (LINCS) Center, Harvard Medical School, Boston, MA, USA 2010-present

Scientific Coordinator of the NIH-NIGMS Cell Decision Process (CDP) Center, Massachusetts Institute of Technology, Cambridge, MA, USA 2008-2012

### Additional Training

Workshop: *Small-sample transcriptomics by stochastic profiling.* Charlottesville, VA, USA 2014

Workshop: *AACR Translational Cancer Research.* Boston, MA, USA 2013

### Honors and Awards

Ph.D. Fellowship, Boehringer Ingelheim Foundation, Mainz, Germany 1999-2002

Visiting Student Fellowship, UC Riverside, Riverside, CA, USA 1997-1998

### Professional Memberships and Activities

American Association for Cancer Research 2011-present

**Advising and Supervision**

<u>Lauren Barney</u> , Ph.D. student, Department of Chemical Engineering, UMass Amherst, Amherst, MA, USA Role: Member of doctoral dissertation committee	2013-present
<u>Nefeli Georgoulia</u> , Ph.D. student, School of Engineering and Applied Science, Harvard University, Cambridge, MA, USA Role: Help in experimental design and trouble shooting; advice in preparing publication and thesis	2012-2014
<u>Simon Gordonov</u> , Visiting Undergraduate Summer Student, Department of Systems Biology, Harvard Medical School, Boston, MA, USA Role: Supervision and experimental planning	2012
<u>Mirra Chung</u> , Senior Technician and Tissue Culture Specialist, Department of Systems Biology, Harvard Medical School, Boston, MA, USA Role: Direct supervision (100%); experimental planning; performance evaluation; career planning	2010-present
<u>Saman Honarnejad</u> , Visiting Research Scholar, Department of Systems Biology, Harvard Medical School, Boston, MA, USA Role: Training and mentoring; help in experimental design and trouble shooting	2010-2015
<u>Lili Zhou</u> , Technician, Department of Systems Biology, Harvard Medical School, Boston, MA, USA Role: Direct supervision (100%); training; experimental planning and trouble shooting; performance evaluation; career planning	2010-2014
<u>Nathan Moerke</u> , Senior Assay Developer and Technician, Department of Systems Biology, Harvard Medical School, Boston, MA, USA Role: Direct supervision (50%); training; experimental planning and trouble shooting; performance evaluation	2010-2012
<u>Daniela Robles</u> , Visiting Undergraduate Summer Student, Department of Systems Biology, Harvard Medical School, Boston, MA, USA Role: Training and mentoring; help in experimental design and trouble shooting	2010
<u>Bjorn Millard</u> , Ph.D. student, Department of Systems Biology, Harvard Medical School, Boston, MA, USA Role: Training and mentoring; help in experimental design and trouble shooting; advice in preparing publication and thesis	2008-2011
<u>Somponnat Sampattavanich</u> , Ph.D. student, Research Laboratory of Electronics at MIT, Cambridge, MA, USA Role: Help in experimental design and trouble shooting; advice in preparing publication and thesis	2008-2011
<u>Sean Milton</u> , Technician, Department of Systems Biology, Harvard Medical School, Boston, MA, USA Role: Direct supervision (50%); training; experimental planning and trouble shooting; performance evaluation	2007-2009

## Publications

### Peer-reviewed publications

1. **Niepel M\***, Hafner M\*, Duan Q, Wang Z, Paull EO, Chung M, Lu X, Stuart JM, Golub TR, Subramanian A, Ma'ayan A, Sorger PK. (under review) *Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling*. Nat Comm.
2. Hafner M, Niepel M, Sorger PK. (submitted) *Better theory for reproducible cancer pharmacogenomics*. Nature
3. **Niepel M\***, Farr JC\*, Rout MP, Strambio-De-Castillia C. (in revision) *Method for the rapid purification of transport-competent nuclei from *Saccharomyces cerevisiae**. Mol Biol Cell.
4. Shi T, **Niepel M**, McDermott JE, Gao Y, Nicora CD, Chrisler WB, Markillie LM, Smith RD, Rodland KD, Sorger PK, Qian W, Wiley HS. (accepted for publication) *Conserved Protein Abundance and Low Adaptor Levels Are Fundamental Features of the EGFR-MAPK Signaling Pathway*. Sci Signal
5. Duan Q, Reid SP, Clark C, Wang Z, Fernandez N, Rouillard AD, Readhead B, Hodos R, Tritesch S, Hafner M, **Niepel M**, Sorger PK, Dudley JT, Bavari S, Panchal RG, Ma'ayan A. (accepted for publication) *L1000CDS2: LINCS L1000 Characteristic Direction Signatures Search Engine*. NPJ Systems Biology and Applications. doi: 10.1038/npsba.2016.15
6. Hafner M\*, **Niepel M\***, Chung M, Sorger PK. (2016) *Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs*. Nat Methods. 13(6): 521-7. doi: 10.1038/nmeth.3853
7. Fallahi-Sichani M, Moerke NJ, **Niepel M**, Zhang T, Gray NS, Sorger PK. (2015) *Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis*. Mol Syst Biol. 11(3):797. doi: 10.15252/msb.20145877.
8. **Niepel M\***, Hafner M\*, Pace EA\*, Chung M, Chai DH, Zhou L, Muhlich JL, Schoeberl B, Sorger PK. (2014) *Molecular determinants of growth factor signaling in genetically diverse breast cancer lines*. BMC Biol. 12:20. doi: 10.1186/1741-7007-12-20.
9. Duan Q\*, Flynn C\*, **Niepel M**, Hafner M, Muhlich JL, Tan CM, Chen EY, Pillai A, Golub TR, Sorger PK, Subramanian A, Ma'ayan A. (2014) *LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures*. Nucleic Acids Res. Web Server issue: W449-60. doi: 10.1093/nar/gku476.
10. Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, **Niepel M**, Thoreen CC, Kang SA, Patricelli MP, Wang Y, Tupper T, Altabel A, Kawamura H, Held KD, Chou DM, Elledge SJ, Janne PA, Wong KK, Sabatini DM, Gray NS. (2013) *Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR*. Cancer Res. 73:2574-2586.
11. McAllister\* FE, **Niepel M\***, Haas,W, Huttlin E, Sorger PK, Gygi SP. (2013) *Mass Spectrometry Based Method to Increase Throughput for Kinome Analyses Using ATP Probes*. Analytical Chemistry. 85:4666-4674.
12. Paull EO, Carlin DE, **Niepel M**, Sorger PK, Haussler D, Stuart JM. (2013) *Discovering causal pathways linking genomic events to transcriptional states using Tied Diffusion Through Interacting Events (TieDIE)*. Bioinformatics. 29(21):2757-64. doi: 10.1093/bioinformatics/btt471
13. **Niepel M**, Molloy KR, Williams R, Farr JC, Meinema AC, Vecchiotti N, Cristea IM, Chait BT, Rout MP, Strambio-De-Castillia C. (2013) *The nuclear basket proteins Mlp1p and Mlp2p are part of a dynamic interactome including Esc1p and the proteasome*. Mol Biol Cell. 24(24):3920-38. doi: 10.1091/mbc.E13-07-0412.
14. **Niepel M\***, Hafner M\*, Pace EA\*, Chung M, Chai DH, Zhou L, Schoeberl B, Sorger PK. (2013) *Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines*. Sci Signal. 6(294):ra84. doi: 10.1126/scisignal.2004379.
15. Liu Q, Kirubakaran S, Hur W, **Niepel M**, Westover K, Thoreen CC, Wang J, Ni J, Patricelli MP, Vogel K, et al. (2012) *Kinome-wide selectivity profiling of ATP-competitive mTOR (mammalian target of rapamycin) inhibitors and characterization of their binding kinetics*. J Biol Chem. 287:9742.
16. Zhang T, Inesta-Vaquera F, **Niepel M**, Zhang J, Ficarro SB, Machleidt T, Xie T, Marto JA, Kim N, Sim T, et al. (2012) *Discovery of potent and selective covalent inhibitors of JNK*. Chem Biol. 19:140–154.
17. Keck JM\*, Jones MH\*, Wong C, Binkley J, Chen D, Holinger EP, **Niepel M**, Rout MP, Vogel J, Sidow A, Yates J, Winey M. (2011) *A Cell Cycle Phosphoproteome of the Yeast Centrosome*. Science 332: 1557.
18. Millard BL, **Niepel M**, Menden MP, Muhlich JL, Sorger PK. (2011) *Adaptive informatics for multifactorial and high-content biological data*. Nat Methods. 8: 487–493.
19. Yang, R\*, **Niepel M\***, Mitchison TK, Sorger PK. (2010) *Dissecting variability in responses to cancer chemotherapy through systems pharmacology*. Clin Pharmacol Ther. 88(1):34-8.
20. Strambio-De-Castillia C, **Niepel M**, Rout MP. (2010) *The nuclear pore complex: bridging nuclear transport and gene regulation*. Nat Rev Mol Cell Biol. 11(7):490-501.
21. Chen WW\*, **Niepel M\***, Sorger PK. (2010) *Michaelis-Menten equations and representations of biochemical*

*reactions as dynamical systems. Genes Dev. 24(17):1861-1875.*

22. Chen WW\*, Schoeberl B\*, Jasper PJ\*, **Niepel M**, Nielsen UB, Lauffenburger DA, Sorger PK. (2009) *Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data. Mol Syst Biol. (5):239.*
23. **Niepel M**\*, Spencer SL\*, Sorger PK. (2009) *Non-genetic cell-to-cell variability and the consequences for pharmacology. Curr Opin Chem Biol. 13(5-6):556-61*
24. **Niepel M**\*, Strambio-de-Castillia C\*, Fasolo J, Chait BT, Rout MP. (2005) *The nuclear pore complex-associated protein, Mlp2p, binds to the yeast spindle pole body and promotes its efficient assembly. J Cell Biol. 170(2):225-35.*
25. Gallie DR, Ling J, **Niepel M**, Morley SJ, Pain VM. (2000) *The role of 5'-leader length, secondary structure and PABP concentration on cap and poly(A) tail function during translation in Xenopus oocytes. Nucleic Acids Res. 28(15):2943-53.*
26. **Niepel M**, Gallie DR. (1999) *Identification and characterization of the functional elements within the tobacco etch virus 5' leader required for cap-independent translation. J Virol. 73(11):9080-8.*
27. **Niepel M**, Ling J, Gallie DR. (1999) *Secondary structure in the 5'-leader or 3'-untranslated region reduces protein yield but does not affect the functional interaction between the 5'-cap and the poly(A) tail. FEBS Lett. 462(1-2):79-84.*

### National/International Meetings, Lectures, and Seminars

1. **Niepel M**. *New methods and better theory for pre-clinical cancer pharmacogenomics. AACR Engineering and Physical Sciences in Oncology.* Boston, MA, USA (6/26/16)
2. **Niepel M**. *Connecting the molecular and phenotypic response to small molecule inhibitors. Department of Pharmacology & Systems Therapeutics Seminar Series at Mt. Sinai.* New York, NY, USA (5/31/16)
3. **Niepel M**\*, Hafner M\*, Sorger PK. *A novel analytical approach to accurately assess in vitro drug responses for breast cancer therapy. Keystone Symposia Modern Phenotypic Drug Discovery: Defining the Path Forward.* Big Sky, MT, USA (4/2016)
4. **Niepel M**\*, Hafner M\*, Sorger PK. *A novel analytical approach to accurately assess in vitro drug responses for breast cancer therapy. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics.* Boston, MA, USA (11/2015)
5. **Hafner M**\*, **Niepel M**\*, Duan Q, Lu X, Paull E, Stuart J, Subramanian A, Ma'ayan A, Sorger PK. *Transcriptional landscape of drug response guides the design of specific and potent drug combinations. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics.* Boston, MA, USA (11/2015)
6. **Niepel M**\*, Hafner M\*, Sorger PK. *A novel analytical approach to accurately assess in vitro drug responses for breast cancer therapy. AACR Advances in Breast Cancer Research.* Bellevue, WA, USA (10/2015)
7. Fallahi-Sichani M, Moerke NJ, **Niepel M**, Zhang T, Gray NS, Sorger PK. *Systematic characterization of drug-induced adaptive responses in melanoma. 2015 Biomedical Engineering Society Annual Meeting.* Paris, France (10/2015)
8. **Shi T**, **Niepel M**, Nicora CD, Gao Y, Fillmore TL, Chrisler WB, Gaffrey MJ, Moore RJ, Liu T, Camp II DJ, Smith RD, Rodland KD, Sorger PK, Wiley HS, Qian WJ. *Absolute quantification of key pathway proteins reveals SOS1 as the bottleneck of ERK response in the Ras-MAPK pathway. 63rd American Society for Mass Spectrometry Conference.* St Louis, MO, USA (5/2015)
9. **Shi T**, Gao Y, Gaffrey M, Chrisler WB, Fillmore TL, Nicora CD, Markillie M, Rodland KD, McDermott J, **Niepel M**, Sorger PK, Smith R1, Wiley SH, Qian WJ. *Global and Targeted Quantification of Seven Human Cell Lines Reveals the Correlation of Cell Type-Specific Responses with Feedback Regulators. 63rd American Society for Mass Spectrometry Conference.* St Louis, MO, USA (5/2015)
10. **Hafner M**\*, **Niepel M**\*, Duan Q, Clark N, Subramanian A, Ma'ayan A, Sorger PK. *Transcriptional landscape of drug response guides the design of specific and potent drug. AACR Special Conference on Computational and Systems Biology of Cancer.* San Francisco, CA, USA (2/2015)
11. Tobe BTD, Crain AM, Winkquist AM, Dorsett L, McCarthy M, McClung C, **Niepel M**, Wada M, Inoue Y, Yamashita N, Li J, Haggarty S, Sorger PK, Shamu C, Sidman RL, Brill LM, Singec I, Halpain S, Goshima Y, **Snyder EY**. *Using a "Molecular Can-opener" to Model Complex Disease: probing lithium's targets in bipolar hiPSCs suggests a novel underlying developmental disorder. 43rd Annual Meeting of the Child Neurology Society.* Columbus, OH, USA. (10/2014)
12. Fallahi-Sichani M, Moerke NJ, **Niepel M**, Zhang T, Gray NS, Sorger PK. *Systematic characterization of drug-induced adaptive responses in melanoma. FEBS EMBO 2014 Conference.* Paris, France (8/2014)

13. Lin JR, Hafner M, **Niepel M**, Berriz G, Sorger PK. *A Quantitative Drug-Target Relationship Network for Analyzing Cellular Response and Poly-pharmacology of Small Molecular Inhibitors in Cancer Therapy*. **International Conference on Systems Biology of Human Disease**. Boston, MA, USA (6/2014)
14. Tobe BT, Crain AM, Winquist AM, Calabrese B, Sidor M, Brandel M, Duerr C, Pernia C, Dorsett L, McCarthy M, McClung C, **Niepel M**, Wada M, Inoue Y, Yamashita N, Li J, Haggarty S, Sorger PK, Shamu C, Sidman RL, Brill LM, Singec I, Halpain S, Goshima Y, Snyder EY. *A Prototypical Strategy for Using "Disease-in-a-Dish" Technology to Model Complex Polygenic Disorders: Probing Lithium's Action in hiPSCs Reveals a Novel Developmental Mechanism in Bipolar Psychopathology With Potentially Broad Pharmacotherapeutic Implications*. **21st Annual Meeting of the American Society for Neural Therapy and Repair**. Clearwater, FL, USA (4/2014)
15. Schoeberl B, **Niepel M**, Hafner M, Pace EA, Chung M, Chai DH, Zhou L Sorger PK. *Basal and induced receptor profiles cluster cell lines into subtypes and predict drug response in a panel of breast cancer lines*. **San Antonio Breast Cancer Symposium**. San Antonio, TX, USA (12/2013)
16. Hafner M\*, **Niepel M\***. *Analyzing and interpreting RTK and signaling measures of breast cancer cell lines from HMS LINCS*. **LINCS Symposium 2013**. Cambridge, MA, USA (11/2013)
17. Hafner M\*, **Niepel M\***, Duan Q, Clark N, Subramanian A, Ma'ayan A, Sorger PK. *L1000 expression signatures reveal the landscape of ligand and drug response in breast cancer cell lines*. **6th Annual RECOMB/ISCB Conference**. Toronto, ON, CA (11/2013)
18. **Niepel M\***, Hafner M\*, Pace E\*, Schoeberl B, Sorger PK. *The receptor tyrosine kinase layer characterizes breast cancer cell lines and predicts sensitivity to therapeutic drugs*. **Merrimack Pharmaceuticals, Inc**. Boston, MA, USA (6/2013)
19. **Niepel M\***, Hafner M\*, Pace E\*, Schoeberl B, Sorger PK. *The receptor tyrosine kinase layer of breast cancer cell lines is predictive of the response to therapeutic drugs*. **AACR 104th Annual Meeting**. Washington, DC, USA (4/2013)
20. **Niepel M\***, Hafner M\*, Pace E\*, Schoeberl B, Sorger PK. *The receptor tyrosine kinase layer characterizes breast cancer cell lines and predicts sensitivity to therapeutic drugs*. **CSHL conference on Cancer Biology & Therapeutics**. Cold Spring Harbor, NY, USA (4/2013)
21. McAllister F, Niepel M, Sorger PK, Gygi SP. *Kinome profiling of six breast cancer cell lines using three different proteomics techniques*. **Tyrosine Kinase Signaling in Cancer, Disease, and Development**. Snowmass, CO, USA (6/2012)
22. **Niepel M\***, Hafner M\*, Pace E\*, Schoeberl B, Sorger PK. *The receptor tyrosine kinase layer of breast cancer cell lines is predictive of the response to therapeutic drugs*. **AACR Chemical Systems Biology Conference**. Boston, MA, USA (6/2012)
23. **Niepel M**, Subramanian A, Golub T, Sorger PK. *Linking the phosphoproteome and transcriptome in oncogenic signaling pathways*. **AACR 102nd Annual Meeting**. Orlando, FL, USA (4/2011)
24. **Niepel M**, Molloy K, Cristea IM, Williams R, Meinema A, Farr JC, Luban J, Chait BT, Rout MP, Strambio-de-Castillia C. *Interactome of the nuclear basket proteins of the yeast nuclear pore complex*. **National Technology Centers for Networks and Pathways Annual All Hands Meeting**. Washington, DC, USA (2/2011)
25. **Niepel M**. *Using high-throughput microscopy to study single cell pharmacology*. **Applied Precision, Inc**. Seattle, WA, USA (7/2010)
26. **Niepel M**, Millard BL, Sorger PK. *Using high-throughput microscopy to study single cell pharmacology*. **Annual NIGMS Systems Biology Centers Meeting**. Seattle, WA, USA (7/2010)
27. Chen W, **Niepel M**, Sorger PK. *Nonidentifiability and Model Calibration in Biochemical Systems*. **International Conference on Systems Biology of Human Disease**. Boston, MA, USA (6/2010)
28. Sampattavanich S, **Niepel M**, Vahey M, Sorger PK, Voldman J. *Regularly-spaced cell patterns for the examination of diffusive intercellular communication between autocrine cells*. **International Conference on Systems Biology of Human Disease**. Boston, MA, USA (6/2010)
29. White CD, Li Z, **Niepel M**, Sacks DB. *IQGAP1 is a novel HER2 binding partner and regulates HER2-mediated cell proliferation*. **Experimental Biology**. Anaheim, CA, USA (4/2010)
30. **Niepel M**, Molloy K, Cristea IM, Williams R, Meinema A, Farr JC, Luban J, Chait BT, Rout MP, Strambio-de-Castillia C. *Interactome of the Nuclear Basket Proteins of the Yeast Nuclear Pore Complex*. **58th American Society for Mass Spectrometry Conference**. Salt Lake City, UT, USA (5/2010)
31. Millard B, **Niepel M**, Sorger PK. *Cell to cell variation in early and late ErbB-signaling exposed by high-throughput microscopy and ImageRail*. **The 10th International Conference on Systems Biology**. Stanford, CA, USA (8/2009)

32. Millard B, **Niepel M**, Sorger PK. *Cell to cell variation in early and late ErbB-signaling exposed by high-throughput microscopy and ImageRail*. **International Conference on Systems Biology of Human Disease**. Boston, MA, USA (6/2009)
33. Millard B, **Niepel M**, Milton S, Sorger PK. *Heterogeneity of breast cancer signaling and its implications about therapeutic efficacy*. **61st Annual Symposium on Cancer Research**. Houston, TX, USA (10/2008)
34. Millard B, **Niepel M**, Milton S, Sorger PK. *Heterogeneity of breast cancer signaling and its implications about therapeutic efficacy*. **International Conference on Systems Biology of Human Disease**. Boston, MA, USA (6/2008)
35. **Niepel M**, Milton S, Chen WW, Jasper P, Sorger PK. *Modeling ErbB signaling in breast cancer cell lines*. **NCI Integrative Cancer Biology Program Annual Meeting**. Washington, DC, USA (11/2007)
36. **Niepel M\***, Strambio-De-Castillia C\*, Fasolo J, Rout MP. *Mlp1p and Mlp2p form a network that interconnects adjacent nuclear pore complexes and confers stability to the nuclear envelope*. **Cold Spring Harbor Laboratory Meeting, Dynamic Organization of Nuclear Function**. Cold Spring Harbor, NY, USA (9/2004)
37. Strambio-De-Castillia C\*, **Niepel M\***, Fasolo J, Rout MP. *The peripheral nuclear protein, Mlp2p, binds Spc42p and promotes the structural integrity and function of the spindle pole body*. **2004 Cold Spring Harbor Laboratory Meeting, Dynamic Organization of Nuclear Function**. Cold Spring Harbor, NY, USA (9/2004)

**References**

Peter K. Sorger, Ph.D.

[peter\\_sorger@hms.harvard.edu](mailto:peter_sorger@hms.harvard.edu)

Otto Kraye Professor of Systems Pharmacology

Harvard Medical School

Department of Systems Biology

200 Longwood Avenue, WAB438

Boston, MA 02115

(617) 432-6902

Assistant: Chris Bird | [christopher\\_bird@hms.harvard.edu](mailto:christopher_bird@hms.harvard.edu)

Timothy J. Mitchison, Ph.D.

[timothy\\_mitchison@hms.harvard.edu](mailto:timothy_mitchison@hms.harvard.edu)

Hasib Sabbagh Professor of Systems Biology

Harvard Medical School

Department of Systems Biology

200 Longwood Avenue, WAB536

Boston, MA 02115

(617) 432-3805

Assistant: Nikoma Baccus | [nikoma\\_baccus@hms.harvard.edu](mailto:nikoma_baccus@hms.harvard.edu)

H. Steven Wiley, Ph.D.

[steven.wiley@pnnl.gov](mailto:steven.wiley@pnnl.gov)

Systems Biology Program

Pacific Northwest National Laboratory

P.O. Box 999

Richland, WA 99352

(509) 371-6551

Assistant: N/A

Michael P. Rout, Ph.D.

[rout@mail.rockefeller.edu](mailto:rout@mail.rockefeller.edu)

Laboratory of Cellular and Structural Biology

The Rockefeller University

1230 York Avenue, Mail Box No 213

New York, NY 10065

(212) 327-7192

Assistant: Beth Anne Hatton | [hattonb@mail.rockefeller.edu](mailto:hattonb@mail.rockefeller.edu)

Nathanael S. Gray, Ph.D.

[nathanael\\_gray@dfci.harvard.edu](mailto:nathanael_gray@dfci.harvard.edu)

Biological Chemistry and Molecular Pharmacology

Dana Farber Cancer Institute | Harvard Medical School

Longwood Center, Room 2209

360 Longwood Avenue

Boston, MA 02115

(617) 582-8590

Assistant: Nicholle Wurie | [nicholle\\_wurie@dfci.harvard.edu](mailto:nicholle_wurie@dfci.harvard.edu)